These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 12672310

  • 1. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
    Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S.
    Lancet; 2003 Mar 29; 361(9363):1077-83. PubMed ID: 12672310
    [Abstract] [Full Text] [Related]

  • 2. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A.
    Circulation; 1993 Jun 29; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Cintron G, Johnson G, Francis G, Cobb F, Cohn JN.
    Circulation; 1993 Jun 29; 87(6 Suppl):VI17-23. PubMed ID: 8500235
    [Abstract] [Full Text] [Related]

  • 4. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN.
    Circulation; 1993 Jun 29; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [Abstract] [Full Text] [Related]

  • 5. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G, Carson P, Francis GS, Cohn JN.
    Circulation; 1993 Jun 29; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [Abstract] [Full Text] [Related]

  • 6. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S, Cobb FR, Cohn JN, Johnson G, Tristani F.
    Circulation; 1993 Jun 29; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [Abstract] [Full Text] [Related]

  • 7. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M.
    N Engl J Med; 1991 Aug 01; 325(5):303-10. PubMed ID: 2057035
    [Abstract] [Full Text] [Related]

  • 8. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P, Johnson G, Fletcher R, Cohn J.
    J Am Coll Cardiol; 1996 Mar 01; 27(3):642-9. PubMed ID: 8606276
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
    Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN.
    Circulation; 1993 Jun 01; 87(6 Suppl):VI49-55. PubMed ID: 8500239
    [Abstract] [Full Text] [Related]

  • 11. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
    Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, Follath F, Goulder M, Willenheimer R, CIBIS-III investigators.
    Eur J Heart Fail; 2011 Jul 01; 13(7):765-72. PubMed ID: 21551161
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P, Ziesche S, Johnson G, Cohn JN.
    J Card Fail; 1999 Sep 01; 5(3):178-87. PubMed ID: 10496190
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
    Parker AB, Yusuf S, Naylor CD.
    Am Heart J; 2002 Dec 01; 144(6):941-7. PubMed ID: 12486418
    [Abstract] [Full Text] [Related]

  • 16. [The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII].
    Dessì-Fulgheri P, Paci MV, Rappelli A.
    Ann Ital Med Int; 1994 Oct 01; 9 Suppl():16S-18S. PubMed ID: 7857751
    [Abstract] [Full Text] [Related]

  • 17. [Value of ACE inhibitors in heart failure (clinical aspects)].
    Riegger AJ.
    Z Kardiol; 1992 Oct 01; 81 Suppl 4():93-6. PubMed ID: 1290309
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
    Cohn JN.
    Drugs; 1994 Oct 01; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.